Equity momentum continued to lapse on Wednesday, the third day in a row markets have struggled to post gains. This sag may simply reflect end of year profit taking as some investors rebalance their portfolios after a stellar year for US stocks.

Macro data continues to be mixed; a solid jobs report mixed with disappointing wage growth data, contributing to the lukewarm environment for the day’s session. Markets await policy news from the Federal Reserve later this week.

Today, we double up on our biopharmaceutical plays for the week. As broader trading momentum sags, investors are more eager than ever to pile into stocks that still have room to grow. After this long bull run, most stocks already have some potential revenue growth baked into their price. Scientific developments can be a useful avenue for NQ users to trade on product development companies that may have been overlooked by the broader market.

 Indeed, this stock has more than doubled so far during today’s trading.

Vistagen Therapeutics (VTGN): Stunning growth on Patent News

Vistagen is a clinical-stage biopharma company focused on developing treatments for clinical depression and other central nervous system disorders.

Today, VTGN announced a new patent on a core technology utilized in their flagship AV-101 development effort. AV-101 is currently in Stage 2 Clinical Trials. It is being studied for use in treating major depressive disorder.

This new approach employs a fundamentally new mechanism of action compared to existing depression treatments.

Investors are betting on the value of this IP in an arena with immense potential revenues on the line: depression and other CNS disorders constitute a massive global market for better treatment options.

 The buying frenzy on Vistagen today has been truly dramatic, with the stock up over 150% at the time of this writing.

Diverse Plays, Great Profits: All in a single news day.

Keep checking our blog for daily updates on lucrative new-based stock plays, analyst actions, and more!

 We analyze news events ranging from clinical trials in the pharmaceutical industry to routine earnings releases to major geopolitical shakeups.

 Or, if you’re ready to move beyond the blog and experience the power of hedge-fund caliber news analysis in a package that’s accessible to small investors, click here to sign up for a free training today. You’ll see how easy to use our platform really is—and how many profitable trades it can unlock

 A powerful news analytics platform like NewsQuantified not only makes it easy to track the news, but to quickly compare news events with key financial information. We make it simple to find strong, diverse plays in any market environment.

 How are you using the news to earn market-beating profits? How would you use the news if you had access to a real-time platform like NewsQuantified?  Let us know in the comments below.

Leave a comment